Corporate Corruption News ArticlesExcerpts of key news articles on corporate corruption
Facebook finally admitted the truth: The "fact checks" that social media use to police what Americans read and watch are just "opinion." That's thanks to a lawsuit brought by celebrated journalist John Stossel, which has exposed the left's supposed battle against "misinformation" as a farce. Stossel posted a pair of videos that touched the third rail of liberal politics – climate change. Neither questioned whether climate change is real, but each talked about other issues, namely forest management and using technology to adapt. Yet the third party that Facebook contracts to review these pieces, Science Feedback, flagged them as "false," or our favorite, "lacking context." Why? Science Feedback didn't like Stossel's "tone." That is, you can't write anything about climate change unless you say it's the worst disaster in the history of humanity and we must spend trillions to fight it. The Post has faced this same gauntlet too many times. In February 2020, we published a column by Steven W. Mosher asking if COVID-19 leaked from the Wuhan Lab. This was labeled "false" by Facebook's fact-checkers. Of course, those supposed "independent" scientific reviewers relied on a group of experts who had a vested interest in dismissing that theory – including EcoHealth, which had funded the Wuhan lab. When Twitter "fact checked" and blocked The Post's stories about Hunter Biden's laptop as "hacked materials," what was the basis? Nothing. It wasn't hacked. Guess they didn't like our tone.
Hospitals are charging up to $650 for a simple, molecular covid test that costs $50 or less to run, according to Medicare claims analyzed for KHN by Hospital Pricing Specialists (HPS). Charges by large health systems range from $20 to $1,419 per test, a new national survey by KFF shows. And some free-standing emergency rooms are charging more than $1,000 per test. The insurance company passes on its higher costs to consumers in higher premiums. Gargantuan volume – 400 million tests and counting, for one type – combined with loose rules on prices have made the service a bonanza for hospitals and clinics. Lab companies have been booking record profits by charging $100 per test. Even in-network prices negotiated and paid by insurance companies often run much more than that. In some cases, hospitals and clinics have supplemented revenue from covid tests with extra charges that go far beyond those for a simple swab. Warren Goldstein was surprised when Austin Emergency Center, in Texas, charged him and his wife $494 upfront for two covid tests. He was shocked when the center billed insurance $1,978 for his test, which he expected would cost $100. His insurer paid $325 for "emergency services" for him, even though there was no emergency. "It seemed like highway robbery," said Goldstein. A World Health Organization cost assessment of running 5,000 covid tests on Roche and Abbott analyzers ... came to $17 and $21 per test, respectively.
The pharmaceutical industry keeps turning up the dial on lobbying, setting massive new spending records in its intensive effort to influence Congress and the Biden administration. Yet this week, President Biden angered drugmakers when he said he supports the waiving of intellectual property protections for coronavirus vaccines. Drug and health product manufacturers, along with their national association, spent a combined $92 million to lobby the federal government from January through March. That puts the industry on track to break its spending record for the second year in a row. Not only that, but its first-quarter spending was more than double what was spent by the second-highest-spending industry, electronics companies. There are currently 1,270 registered lobbyists for pharmaceuticals and health products – more than two lobbyists for every member of Congress. Pfizer, maker of one of the three coronavirus vaccines approved for emergency use in the United States, was the biggest spender of any individual drug company. And last year, as it was developing its vaccine, the federal government agreed to pay the company $1.95 billion for the first 100 million doses it produced. The company reported it had $3.5 billion in revenue from sales of the vaccine so far this year. Pfizer was outflanked on lobbying spending only by the Pharmaceutical Research and Manufacturers of America – the national association that represents the interests of drugmakers.
Global banks faced a fresh scandal about dirty money on Monday as they sought to limit the fallout from a cache of leaked documents showing they transferred more than $2 trillion in suspect funds over nearly two decades. Britain-based HSBC Holdings Plc, Standard Chartered Plc and Barclays Plc, Germany's Deutsche Bank AG and Commerzbank AG, and U.S.-headquartered JPMorgan Chase & Co and Bank of New York Mellon Corp were among the lenders named in the report by the International Consortium of Investigative Journalists and based on leaked documents. The report was based on 2,100 leaked suspicious activity reports (SARs), covering transactions between 1999 and 2017, filed by banks and other financial firms with the U.S. Department of Treasury's Financial Crimes Enforcement Network (FinCEN). Banks are required to file an SAR whenever handling funds that cause grounds for suspicion of criminal activity. The reports revealed broader problems with the monitoring system at the heart of global policing of money laundering and other criminal activity. Investors worried about the potential fallout for global banks, many of which have faced hefty fines in the past for lapses in controls and spent billions of dollars to bolster compliance. "It confirms what we already knew: that there are huge amounts of SARs being filed with relatively low numbers of cases brought through to prosecution,” said Etelka Bogardi, a Hong Kong-based financial services partner at Norton Rose Fulbright. "It also brings out the point that managing financial crime risk goes beyond making SARs," Bogardi said.
Note: The original ICIJ report is titled “Global banks defy U.S. crackdowns by serving oligarchs, criminals and terrorists.” Compare with the title of the New York Times article on this, “Banks Suspected Illegal Activity, but Processed Big Transactions Anyway.” A search on this topic shows that headlines of almost all major media have watered this down, likely to not upset the big banks. For more along these lines, see concise summaries of deeply revealing news articles on financial industry corruption from reliable major media sources.
The nursing home industry has been devastated by the coronavirus, with outbreaks killing thousands of elderly residents. But the health crisis presents operators with a potential financial upside. Patients with COVID-19 could be worth more than four times what homes are able to charge for long-term residents with relatively mild health issues. Some patient advocates and industry experts fear the premium pay available for coronavirus patients – and a simultaneous easing of regulations around transfers – could tempt some home operators to move out low-paying residents to bring in more lucrative COVID-19 patients, despite the obvious health risks to residents and staff. "There are probably some unscrupulous operators who would jump at this," said David Grabowski, a professor of healthcare policy at Harvard Medical School. A new Medicare reimbursement system that went into effect last fall pays nursing homes substantially more for new patients – including those released from a hospital – particularly for the first few weeks. Under those guidelines, COVID-19 patients can bring in upward of $800 per day. By contrast, facilities collect as little as $200 per day for long-term patients with dementia. Nursing homes have always had a financial incentive to attract the short-term patients ... Grabowski said. But the health risks for existing residents and staff are so high with COVID-19, Grabowski said, "I'd be a little suspicious of a low-quality nursing home that's jumping to the head of the line for this."
Note: Another excellent article presents more important questions on how this might skew death statistics for the coronavirus. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.
Mr. Ton-That — an Australian techie and onetime model — did something momentous: He invented a tool that could end your ability to walk down the street anonymously. His tiny company, Clearview AI, devised a groundbreaking facial recognition app. You take a picture of a person, upload it and get to see public photos of that person, along with links to where those photos appeared. The system — whose backbone is a database of more than three billion images that Clearview claims to have scraped from Facebook, YouTube, Venmo and millions of other websites — goes far beyond anything ever constructed by the United States government or Silicon Valley giants. Without public scrutiny, more than 600 law enforcement agencies have started using Clearview in the past year. The computer code underlying its app ... includes programming language to pair it with augmented-reality glasses; users would potentially be able to identify every person they saw. The tool could identify activists at a protest or an attractive stranger on the subway, revealing not just their names but where they lived, what they did and whom they knew. And it’s not just law enforcement: Clearview has also licensed the app to at least a handful of companies for security purposes. Because the police upload photos of people they’re trying to identify, Clearview possesses a growing database of individuals who have attracted attention from law enforcement. The company also has the ability to manipulate the results that the police see.
Note: For lots more on this disturbing new technology, read one writer's personal experience with it. For more along these lines, see concise summaries of deeply revealing news articles on the disappearance of privacy from reliable major media sources.
What happens when government leaders leave Washington for cushy jobs on corporate boards? Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb is just the latest administration official to go through the revolving door after his second tour at the FDA. Gottlieb recently resigned from his spot as the top federal drug regulator to take on a role at Pfizer–the top drug producer in the United States. But Gottlieb's hiring is just the latest in a long line of moves to fortify the industry's influence in Washington. Big Pharma spending on lobbying eclipses every other industry according to the Center for Responsive Politics. Current Health and Human Services Secretary Alex Azar - Gottlieb's former boss - used to be president of Lilly USA, the U.S. branch of pharmaceutical giant Eli Lilly. Trump lauded his appointment by calling Azar a "star for better healthcare and lower drug prices," but during his time there the company raised the brand's insulin prices threefold creating a crisis and drawing public outrage. A study last year found more than 160 former lobbyists serving in the Trump administration - and those industry ties point to an administration that puts the priorities of large corporations over those of the American people. Corporate executives and industry lobbyists cannot be effective regulators of the industries that have made them millions. The revolving door is an age-old problem in Washington but the scope and volume of the conflicts in the current administration ... is unprecedented.
Note: For lots more on the revolving door between government and big Pharma, see the "Revolving Door Project" and read this revealing article. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and Big Pharma profiteering from reliable major media sources.
Laurie Valeriano first heard about DINP decades ago. "I started to worry about the chemicals that come out of all these plastics," she said. DINP, one of a group of chemicals called phthalates that makes plastic more pliable, was one of them. It was already clear that DINP could cause cancer and interfere with hormonal functioning. In February 2000, Valeriano and her employer, the Washington Toxics Coalition, asked the Environmental Protection Agency to add DINP to the list of chemicals it monitors through a nationwide program called the Toxics Release Inventory. Seven months later ... the EPA announced that it planned to grant the group's request and issued a proposed rule that would add DINP to the toxics inventory. Yet more than 20 years later, the EPA has yet to make good on its promise to add DINP to the list of chemicals. It never finalized the rule. Companies have continued to churn out DINP ... in astounding amounts without disclosing how much individual plants make and emit. In addition to the cancer and hormone disruption that sparked Valeriano's claim 21 years ago, we now know more about how DINP affects the sexual development of children. It decreases sperm motility, increases malformations of the testes and other organs, and makes boys ... more likely to be infertile later in life. In fact, the entire group of phthalates – an estimated half-billion pounds of which are made and used in the U.S. each year – seem to cause a similar constellation of health problems.
Just as the Biden administration is pushing to raise taxes on corporations, a new study finds that at least 55 of America's largest firms paid no taxes last year on billions of dollars in profits. The sweeping tax bill passed in 2017 by a Republican Congress and signed into law by President Donald Trump reduced the corporate tax rate to 21% from 35%. But dozens of Fortune 500 companies were able to further shrink their tax bill – sometimes to zero – thanks to a range of legal deductions and exemptions that have become staples of the tax code. Salesforce, Archer-Daniels-Midland and Consolidated Edison were among those named in the report, which was done by the Institute on Taxation and Economic Policy. Twenty-six of the companies listed, including FedEx, Duke Energy and Nike, were able to avoid paying any federal income tax for the last three years even though they reported a combined income of $77 billion. Many also received millions of dollars in tax rebates. Publicly traded corporations are required to file financial reports. The institute used that data along with other information supplied by each company. The $2.2 trillion coronavirus relief act ... contained a provision that temporarily allowed businesses to use losses in 2020 to offset profits earned in previous years. Tax avoidance strategies include a mix of old standards and new innovations. Companies, for example, saved billions by allowing top executives to buy discounted stock options in the future and then deducting their value as a loss.
Note: For more along these lines, see concise summaries of deeply revealing news articles on corporate corruption from reliable major media sources.
During New York Gov. Andrew Cuomo’s daily coronavirus briefing on Wednesday, the somber grimace that has filled our screens for weeks was briefly replaced by something resembling a smile. The inspiration ... was a video visit from former Google CEO Eric Schmidt, who joined the governor’s briefing to announce that he will be heading up a blue-ribbon commission to reimagine New York state’s post-Covid reality, with an emphasis on permanently integrating technology into every aspect of civic life. Just one day earlier, Cuomo had announced a similar partnership with the Bill and Melinda Gates Foundation to develop “a smarter education system.” It has taken some time to gel, but something resembling a coherent Pandemic Shock Doctrine is beginning to emerge. Call it the “Screen New Deal.” Far more high-tech than anything we have seen during previous disasters, the future that is being rushed into being as the bodies still pile up treats our past weeks of physical isolation not as a painful necessity to save lives, but as a living laboratory for a permanent — and highly profitable — no-touch future. This is a future in which, for the privileged, almost everything is home delivered, either virtually via streaming and cloud technology, or physically via driverless vehicle or drone, then screen “shared” on a mediated platform. It’s a future in which our every move, our every word, our every relationship is trackable, traceable, and data-mineable by unprecedented collaborations between government and tech giants.
Before the coronavirus virus crushed the US stock market, the Republican senator Richard Burr apparently used information he gleaned from his role as chairman of the Senate intelligence committee about the ferocity of the coming pandemic to unload 33 stocks held by him and his spouse. They were estimated at being worth between $628,033 and $1.72m. While publicly parroting Trump’s happy talk at the time, Burr confided to several of his political funders that the disease would be comparable to the deadly 1918 flu pandemic. When society faces a common threat, exploiting a special advantage is morally repugnant. Call it “Burring”. The coronavirus should have altered business as usual. But last week’s Senate Republican relief package, giving airlines $58bn and billions more to other industries, is pure Burring. Walmart, the largest employer in America, doesn’t give its employees paid sick leave. 88% of Walmart employees report sometimes coming to work when sick. None of the giants of the fast-food industry – McDonald’s, Burger King, Pizza Hut, Duncan Donuts, Wendy’s, Taco Bell, Subway – gives their workers paid sick leave, either. Amazon, one of the richest corporations in the world, which paid almost no taxes last year, is offering unpaid time off for workers who are sick. These corporations have made sure they and other companies with more than 500 employees are exempt from the requirement in the House coronavirus bill that employers provide paid sick leave.
Note: Read a New York Times article for further information on how Senator Burr, the head of the US Senate Intelligence Committee, after being briefed of impending disaster, unloaded $1 million in investments while telling the public everything was fine. Read an article in The Atlantic showing how the Coronavirus is giving the world's leaders a rich opportunity for a power grab. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus pandemic from reliable major media sources.
On Sept. 7, 2017, the world heard an alarming announcement from credit ratings giant Equifax: In a brazen cyberattack, somebody had stolen sensitive personal information from more than 140 million people, nearly half the population of the U.S. The information included Social Security numbers, driver's license numbers, information from credit disputes and other personal details. Then, something unusual happened. The data disappeared. Completely. CNBC talked to eight experts. All of them agreed that a breach happened, and personal information from 143 million people was stolen. But none of them knows where the data is now. Security experts haven't seen the data used in any of the ways they'd expect in a theft like this — not for impersonating victims, not for accessing other websites, nothing. Most experts familiar with the case now believe that the thieves were working for a foreign government and are using the information not for financial gain, but to try to identify and recruit spies. One former senior intelligence official ... summarized the prevailing expert opinion on how the foreign intelligence agency is using the data. First, he said, the foreign government is probably combining this information with other stolen data, then analyzing it using artificial intelligence or machine learning to figure out who's likely to be — or to become — a spy for the U.S. government. Second, credit reporting data provides compromising information that can be used to turn valuable people into agents of a foreign government.
British drug giant GlaxoSmithKline has finally admitted that thousands of babies in this country were inoculated with a batch of toxic whooping cough vaccines in the 1970s. Some experts believe that these Trivax vaccines - which had not passed critical company safety tests - may have caused permanent brain damage and even fatalities in young children. In 1992, the family of an Irish boy, Kenneth Best, who suffered brain damage from one of these toxic vaccines, was awarded Ł2.7 million in compensation by the Irish Supreme Court. The boy's family finally won this historic case after his mother Margaret made a startling find when sifting through tens of thousands of company documents. She discovered that the Trivax vaccine used on her son, from a batch numbered 3,741, had been released by the company despite it having failed to pass a critical safety test. Documents revealed that the 60,000 individual doses within this batch were known to be 14 times more potent than normal. Last year an investigation by The Observer found evidence to suggest that vaccines from this faulty batch ... had also been used in Britain. Liberal Democrat MP Norman Baker raised questions in the House of Commons, asking whether vaccines from this batch had been given to British babies. Then Health Minister Yvette Cooper wrote to the company asking for information. Now, almost a year later, GlaxoSmithKline has replied that it is 'highly probable' the toxic batches had been used in Britain.
Note: For more along these lines, see concise summaries of deeply revealing news articles on vaccine risks from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.
A colonoscopy might cost you or your insurer a few hundred dollars – or several thousand, depending on which hospital or insurer you use. Long hidden, such price variations are supposed to be available in stark black and white under a Trump administration price transparency rule that took effect at the start of this year. It requires hospitals to post a range of actual prices – everything from the rates they offer cash-paying customers to costs negotiated with insurers. While imperfect and potentially of limited use right now to the average consumer, the disclosures that are available illustrate the huge differences in prices – nationally, regionally and within the same hospital. Prices are all over the map. In Virginia, for example, the average price of a diagnostic colonoscopy is $2,763, but the range across the state is from $208 to $10,563. Patients can try to find the price information themselves by searching hospital websites, but even locating the correct tab on a hospital's website is tricky. But if you do want to try, here's one tip: "You can Google the hospital name and the words 'price transparency' and see where that takes you," says Caitlin Sheetz, director and head of analytics at the consulting firm ADVI Health. When it comes to compliance, "we're seeing the range of the spectrum," says Jeffrey Leibach, a partner at the consulting firm Guidehouse, which found earlier this year that about 60% of 1,000 hospitals surveyed had posted at least some data, but 30% had reported nothing at all.
Note: For more along these lines, see concise summaries of deeply revealing news articles on health from reliable major media sources.
In "Why the Innocent Plead Guilty and the Guilty Go Free: And Other Paradoxes of Our Broken Legal System," [Judge Jed S.] Rakoff reaches far beyond corporate boardrooms to highlight an array of shortcomings within the criminal justice system. His proposed fixes are worthy of consideration but also lay bare a harsh reality: The entrenched interests tolerating the system's inequities and, in some cases, profiting from the status quo pose significant obstacles to reform. Rakoff realized that America's "system of justice is failing its mission" after becoming a federal district court judge a quarter-century ago. What's the nature of this failure? The country imprisons millions of indigent Americans yet routinely allows white-collar criminals to avoid punishment. "To a federal judge," he declares, the government's reluctance to hold executives accountable and instead enter into "cosmetic prosecution agreements" with corporations that are repeatedly violated and unenforced "is disturbing ... in what it says about the DOJ's apparent disregard for equality under the law." Rakoff fittingly cites Pfizer to exemplify his point. The four deferred-prosecution agreements between the pharmaceutical giant and federal authorities from 2002 to 2009 – all devised to prevent future misconduct – failed to stop the company from flouting the law. Through it all, Pfizer's executives went unpunished, and the fines the company paid represented a fraction of its ill-gotten gains.
Note: For a much deeper analysis and discussion of Judge Rakoff's highly revealing book by courageous journalist Matt Taibbi, see this excellent essay. Consider subscribing to Taibbi's excellent work. For more along these lines, see concise summaries of deeply revealing news articles on corruption in the court system and in Big Pharma from reliable major media sources.
The announcement this week that a cheap, easy-to-make coronavirus vaccine appeared to be up to 90 percent effective was greeted with jubilation. But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine's apparently spectacular efficacy will hold up under additional testing. Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results. The regimen that appeared to be 90 percent effective was based on participants receiving a half dose of the vaccine followed a month later by a full dose; the less effective version involved a pair of full doses. AstraZeneca disclosed in its initial announcement that fewer than 2,800 participants received the smaller dosing regimen, compared with nearly 8,900 participants who received two full doses. Moncef Slaoui, the head of Operation Warp Speed, the U.S. initiative to fast-track coronavirus vaccines, noted another limitation in AstraZeneca's data. On a call with reporters, he suggested that the participants who received the half-strength initial dose had been 55 years old or younger. The fact that the initial half-strength dose wasn't tested in older participants, who are especially vulnerable to Covid-19, could undermine AstraZeneca's case to regulators that the vaccine should be authorized for emergency use.
Note: Learn in this revealing article how vaccine trials are rigged. This article spells out how vaccine makers are above the law and face no consequences for damage from vaccines. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.
On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. The race is on to develop a coronavirus vaccine, and some companies and investors are betting that the winners stand to earn vast profits from selling hundreds of millions – or even billions – of doses to a desperate public. Across the pharmaceutical and medical industries, senior executives and board members ... are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March. Senior officials appear to be pouncing on opportunities to cash out. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. Some companies are attracting government scrutiny for ... using their associations with Operation Warp Speed as marketing ploys. Vaxart's news release declared: "Vaxart's Covid-19 Vaccine Selected for the U.S. Government's Operation Warp Speed." But Vaxart is not among the companies selected to receive significant financial support from Warp Speed.
Note: MSN strangely removed this article a few days after posting it. A similar article by the New York Times titled "The race for a coronavirus vaccine is making some corporate insiders very rich" is available here. For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.
An explosive leak of tens of thousands of documents from the defunct data firm Cambridge Analytica is set to expose the inner workings of the company that collapsed after the Observer revealed it had misappropriated 87 million Facebook profiles. More than 100,000 documents relating to work in 68 countries that will lay bare the global infrastructure of an operation used to manipulate voters on “an industrial scale” are set to be released over the next months. The documents were revealed to have come from Brittany Kaiser, an ex-Cambridge Analytica employee turned whistleblower, and to be the same ones subpoenaed by Robert Mueller’s investigation into Russian interference in the 2016 presidential election. Kaiser ... decided to go public after last month’s election in Britain. “It’s so abundantly clear our electoral systems are wide open to abuse,” she said. “I’m very fearful about what is going to happen in the US election later this year.” Kaiser said the Facebook data scandal was part of a much bigger global operation that worked with governments, intelligence agencies, commercial companies and political campaigns to manipulate and influence people. The unpublished documents contain material that suggests the firm was working for a political party in Ukraine in 2017 even while under investigation as part of Mueller’s inquiry and emails that Kaiser says describe how the firm helped develop a “sophisticated infrastructure of shell companies that were designed to funnel dark money into politics”.
Note: For more along these lines, see concise summaries of deeply revealing news articles on elections corruption from reliable major media sources.
Paul Marik, MD, one of the most highly published critical care physicians in the world and the Director of the ICU at Sentara Norfolk General Hospital, was recently told by Sentara Healthcare that he could no longer administer a range of highly effective COVID-19 treatments to critically ill patients - the same treatments he has successfully used to reduce COVID deaths in the ICU by as much as 50%. The result of the prohibition has been a sharp increase in patient mortality. Because Dr. Marik can no longer stand by while patients needlessly die without proper treatment, he has filed a lawsuit to allow him and his colleagues to administer the combination of FDA-approved drugs and other therapies that has saved thousands of critically ill COVID-19 patients in the last 18 months. The Complaint filed today in the Circuit Court for the City of Norfolk, Virginia states that Sentara Healthcare is "preventing terminally ill COVID patients from exercising their right to choose and to receive safe, potentially life-saving treatment determined to be appropriate for them by their attending physician." Under Virginia law, every patient has the right to receive treatment deemed appropriate for them by their attending physician, and terminally ill patients have the right to try investigational medicines that their treating physician recommends. Through its arbitrary prohibition of the COVID-19 treatment protocol ... Sentara is violating the law and unjustly depriving critically ill patients of lifesaving treatment.
Note: Watch a video detailing successes with these treatments and obstruction by authorities of these life-saving treatments. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.
Lowering prescription drug prices is among the Biden administration's most urgent priorities. But the drug industry is spending big to keep that from happening. A new compromise on Capitol Hill would offer some relief from high prices by gradually allowing Medicare to negotiate drug prices similar to private insurers for the first time, while capping out of pocket costs at $2,000 and setting limits on the cost of insulin. The pharmaceutical industry has spent nearly $263 million on lobbying so far this year, employing three lobbyists for every member of Congress, according to OpenSecrets, which tracks money in politics. Millions of those dollars are in the form of campaign donations. "They have really endless resources to throw at shaping the outcomes of legislation," said Sheila Krumholz, the executive director of OpenSecrets. Congressman Scott Peters, a Democrat, sparked protests outside his San Diego district office when he came out against a plan to cut drug costs for seniors earlier this year. He's received nearly $130,000 from the industry this year. About $100,000 has been donated to Democratic Senator Kyrsten Sinema this year. Senator Robert Menendez, also a Democrat, has taken nearly $80,000 in 2021. "Bottom line is I'm supporting a price negotiation bill that has been worked out," ... Menendez said when asked what message he's sending by taking money from the pharmaceutical industry.
Note: This article fails to mention that big Pharma spends more than any other sector on lobbying and also is the largest sponsor of advertising in the major media. Do you think the media and Congress are biased by this? For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry from reliable major media sources.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.